Wednesday, January 15, 2025
1/15/2025
DESCRIPTION (provided by applicant): The abnormal accumulation of ¿-amyloid (A¿) in the brain is believed to play a pivotal role in the etiology and pathogenesis of Alzheimer's disease (AD). A¿ is produced continuously in the brain, but under normal circumstances its accumulation is prevented by its rapid catabolism. Compared to the breadth of knowledge concerning the enzymes and pathways involved in A¿ production, relatively little research has been devoted to understanding A¿ removal. Two lines of evidence indicate that endothelin-converting enzyme (ECE)-2 is an A¿ degrading enzyme that regulates steady-state levels of the peptide in the brain, and that alterations in its activity potentially contribute to AD pathogenesis. First, we have shown that the steady-state levels of endogenous A¿ are increased in the brains of mice deficient in ECE-2, similar to that observed in animals transgenic for AD-causing presenilin mutations. Second, ECE2 has been shown to be the single most down- regulated gene in AD brain by microarray analysis. Based on these data, our working hypothesis is that alterations in ECE-2 activity influence AD pathogenesis. We will test this hypothesis in three interrelated Aims that examine the ability of ECE-2 to directly degrade A¿ in vitro and promote alterations in pathology in vivo in animal models. In addition, we will examine ECE-2 expression in our large series of brain tissue from autopsy- confirmed AD cases and age-matched controls and identify and analyze genetic variants in ECE2 to determine whether these correlate with alterations in gene expression and susceptibility to late-onset AD (LOAD).
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).